This clinical-stage biotech develops oral therapies for chronic diseases, with a lead candidate targeting type-2 diabetes and obesity.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Renewed pharma interest in GPCR biology and radioligand therapies is drawing attention to functional peptide screening ...

This clinical-stage biotech develops oral therapeutics for chronic diseases, with a pipeline centered on metabolic and ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Only two months after snagging $150 million from investors to take its first G-protein-coupled receptor (GPCR) drug into the clinic, Septerna has added another $47.5 million to the pile courtesy of a ...

It is a characteristic of cell membrane receptors, which is shared by GPCRs along with G-protein associates. The process of receptor oligomerization is assisted by the cell thermodynamics as well as ...

G protein-coupled receptors (GPCRs) remain one of the most pharmacologically successful drug targets, with 35% of all commercial drugs and 19% of newly approved drugs targeting this protein ...

New company (“NewCo”) co-founded by Nxera with a syndicate of leading healthcare and life sciences-focused investment firms.In return for ...